Hu, Chunhong
Second Xiangya Hospital of Central South University
4 papers on CoChatORCID 0000-0003-3857-4598
Most cited papers
- Verified
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 4,081
- Verified
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
Wang, J., Lu, S., Yu, X., Hu, Y., Sun, Y., Wang, Z., Zhao, J., Yu, Y., Hu, C., Yang, K., et al. (2021) · JAMA Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 396
- Verified
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
Qin, S., Li, J., Wang, L., Xu, J., Cheng, Y., Bai, Y., Li, W., Xu, N., Lin, L.-Z., Wu, Q., et al. (2018) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 237
- Verified
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
Zhou, C., Wang, Z., Sun, M., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Sun, S., Chen, J., et al. (2025) · The Lancet Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 23
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free